

---

## ESOCAP ANNOUNCES ISSUE OF A PATENT IN AUSTRALIA FOR ITS SMART APPLICATION TECHNOLOGY IN THE UPPER GASTROINTESTINAL TRACT

*Basel, Switzerland, May 25, 2021*

**EsoCap AG today announced the issue, by the Patent and Trademark Office, of a patent in Australia under no. 2015371725, based on patent application no. 2017132866/04 (057778). The patent is directed at the smart application technology enabling effective topical treatment of several esophageal diseases. “Continued recognition from global jurisdictions validates EsoCap technology’s novelty,” commented Isabelle Racamier, EsoCap AG CEO. “These latest acknowledgments are significant in the context of advancing EsoCap into Phase II clinical development.”**

Up to now, local treatment of diseases of the esophagus has not been possible due to the ultra-short transit time of conventional drug formulations. “EsoCap smart application technology enables targeted and long-lasting local therapy of the esophagus for the first time,” said Dr. Peter Stangier, EsoCap AG’s Director Strategic Planning.



### About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short contact time of drugs, of one to two seconds, from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit [www.esocap-biotech.com](http://www.esocap-biotech.com).

### Contact:

Isabelle Racamier, CEO

EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)